Research
Hormonal
PLIN2 and PLIN3 regulate lipid droplet hydrolysis in non-adipose tissues but are less effective barriers against lipases than PLIN1, and do not compensate for PLIN1 loss in white adipose tissue.
While PLIN1 is the main protector of fat in fat cells, other proteins (PLIN2/3) handle fat storage in other organs like the liver and muscle. These other proteins are less strict barriers, allowing for more flexible fat usage in tissues that need energy, such as heart and muscle.
GoodQualifiesHIGH confidence
In contrast to unphosphorylated Plin1a, Plin2 and 3 are less efficient in protecting CLDs against lipase recruitment... Plin2 does not compensate for Plin1 to regulate WAT lipolysis.
Why this rating
Based on cell culture and mouse model studies.
Source
The Perilipins: Major Cytosolic Lipid Droplet–Associated Proteins and Their Roles in Cellular Lipid Storage, Mobilization, and Systemic Homeostasis
Alan R. Kimmel et al. · Annual Review of Nutrition · 2016
DOI 10.1146/annurev-nutr-071813-105410
narrative_reviewCited 278×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Perilipin 1 (PLIN1) acts as a gatekeeper for lipid storage by sequestering lipases (ATGL and HSL) from cytosolic lipid droplets in the basal state, thereby suppressing lipolysis until hormonal stimulation triggers phosphorylation and enzyme recruitment.Strong
- Defective lipid storage capacity in white adipose tissue, often due to impaired expansion or PLIN dysfunction, leads to ectopic fat deposition in non-adipose tissues, causing insulin resistance and type 2 diabetes.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →